Financiado en parte por Mars Symbioscience
Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial
Virtanen JK, Nurmi T, Aro A, Bertone-Johnson ER, Hyppönen E, Kröger H, Lamberg-Allardt C, Manson JE, Mursu J, Mäntyselkä P, Suominen S, Uusitupa M, Voutilainen A, Tuomainen TP, Hantunen S
The American journal of clinical nutrition · 94 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Organización sin fines de lucro
- Foundation for Cardiovascular Research
- Universidad u hospital
- Itä-Suomen Yliopisto
- Organización sin fines de lucro
- Medicinska Understödsföreningen Liv och Hälsa
- Empresa
- Mars Symbioscience
- Gobierno
- Academy of Finland
- Organización sin fines de lucro
- Suomen Kulttuurirahasto
- Organización sin fines de lucro
- Juho Vainion Säätiö
- Organización sin fines de lucro
- Sydäntutkimussäätiö
- Organización sin fines de lucro
- Diabetestutkimussäätiö
- Organización sin fines de lucro
- Tour de Cure
- Gobierno
- National Institutes of Health
- Gobierno
- Medical Research Council
- Gobierno
- National Health and Medical Research Council
- Gobierno
- Medical Research Future Fund
- Subvenciones
- Academy of Finland (137826)
Según 14 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-12-30 · Am J Clin Nutr · vol. 115 · número 5 · págs. 1300–1310
- Editorial
- Elsevier BV
- Citado
- 126 citas · más que el 99% de estudios similares · 11.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 23 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Vitamin D Research Studies · Nutritional Studies and Diet · Antioxidant Activity and Oxidative Stress
- Palabras clave
- vitamin D3 supplementation, vitamin D insufficiency, cardiovascular disease prevention, cancer prevention, cardiovascular disease incidence, myocardial infarction, stroke, cardiovascular mortality, cancer mortality, older adults, serum 25-hydroxyvitamin D, dose-response relationship, CYP27B1, CYP24
- MeSH
- humans, neoplasms, cardiovascular diseases, vitamin d deficiency, cholecalciferol, vitamins, vitamin d, double-blind method, dietary supplements, aged, finland, female, male
15 autores
- Jyrki K. Virtanen🇫🇮 · autor de correspondenciaUniversity of Eastern Finland
- Tarja Nurmi🇫🇮University of Eastern Finland
- Antti Aro
- Elizabeth R. Bertone‐Johnson🇺🇸University of Massachusetts Amherst
- Elina Hyppönen🇦🇺University of South Australia; South Australian Health and Medical Research Institute
- Heikki Kröger🇫🇮University of Eastern Finland; Kuopio University Hospital
- Christel J. E. Lamberg-Allardt🇫🇮University of Helsinki
- JoAnn E. Manson🇺🇸Brigham and Women's Hospital; Harvard University
- Jaakko Mursu🇫🇮University of Eastern Finland
- Pekka T Mäntyselkä🇫🇮University of Eastern Finland; Kuopio University Hospital
- Sakari Suominen🇫🇮🇸🇪University of Turku; University of Skövde; Turku University Hospital
- Matti I.J. Uusitupa🇫🇮University of Eastern Finland
- Ari Voutilainen🇫🇮University of Eastern Finland
- Tomi‐Pekka Tuomainen🇫🇮University of Eastern Finland
- Sari Hantunen🇫🇮University of Eastern Finland
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Vitamin D insufficiency is associated with risks of cardiovascular diseases (CVD) and cancer in observational studies, but evidence for benefits with vitamin D supplementation is limited.
Objectives
To investigate the effects of vitamin D3 supplementation on CVD and cancer incidences.
Methods
The study was a 5-year, randomized, placebo-controlled trial among 2495 male participants ≥60 years and post-menopausal female participants ≥65 years from a general Finnish population who were free of prior CVD or cancer. The study had 3 arms: placebo, 1600 IU/day, or 3200 IU/day vitamin D3. Follow-up was by annual study questionnaires and national registry data. A representative subcohort of 551 participants had more detailed in-person investigations. The primary endpoints were incident major CVD and invasive cancer. Secondary endpoints included the individual components of the primary CVD endpoint (myocardial infarction, stroke, and CVD mortality), site-specific cancers, and cancer death.
Results
During the follow-up, there were 41 (4.9%), 42 (5.0%), and 36 (4.3%) major CVD events in the placebo, 1600 IU/d (compared with placebo: HR: 0.97; 95% CI: 0.63-1.49; P = 0.89), and 3200 IU/d (HR: 0.84; 95% CI: 0.54-1.31; P = 0.44) arms, respectively. Invasive cancer was diagnosed in 41 (4.9%), 48 (5.8%), and 40 (4.8%) participants in the placebo, 1600 IU/d (HR: 1.14; 95% CI: 0.75-1.72; P = 0.55), and 3200 IU/d (HR: 0.95; 95% CI: 0.61-1.47; P = 0.81) arms, respectively. There were no significant differences in the secondary endpoints or total mortality. In the subcohort, the mean baseline serum 25-hydroxyvitamin D concentration was 75 nmol/L (SD, 18 nmol/L). After 12 months, the concentrations were 73 nmol/L (SD, 18 nmol/L), 100 nmol/L (SD, 21 nmol/L), and 120 nmol/L (SD, 22 nmol/L) in the placebo, 1600 IU/d, and 3200 IU/d arms, respectively.
Conclusions
Vitamin D3 supplementation did not lower the incidences of major CVD events or invasive cancer among older adults, possibly due to sufficient vitamin D status in most participants at baseline.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.